IDH-wildtype glioblastoma

Summary

IDH-wildtype glioblastoma (MONDO:0850335) is a disease and 2 clinical trials. Molecularly, EGFR::WIF1 Fusion confers sensitivity to Bevacizumab in IDH-wildtype Glioblastoma (CIViC Level B). Top therapeutic interventions include fludeoxyglucose f 18. A subtype of glioblastoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	IDH-wildtype glioblastoma
Mondo ID	MONDO:0850335
DOID	DOID:0080878
NCIT	C39750
GARD	0026603
Is cancer (heuristic)	no

Disease family

This is a subtype of glioblastoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › astrocytic tumor › high grade astrocytic tumor › glioblastoma › IDH-wildtype glioblastoma

Related subtypes (6): classical glioblastoma, proneural glioblastoma, mesenchymal glioblastoma, neural glioblastoma, brain glioblastoma, adult glioblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07089641	PHASE1	RECRUITING	ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
NCT06850766	Not specified	RECRUITING	The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUDEOXYGLUCOSE F 18	4	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items; also 2 oncogenic.

Molecular subtype	Therapy	Effect	Level	CIViC
EGFR::WIF1 Fusion	Bevacizumab	Sensitivity/Response	CIViC B	EID11104